Mitsubishi Tanabe Pharma Corporation



Q1 FY2016 Business Results (April-June, 2016)

August 2, 2016

Eizo Tabaru

Board Director, Managing Executive officer General Manager of Finance & Accounting Dept.

Open Up the **Future**

Q1 FY2016 Business Results

The Company has voluntary applied IFRS from FY2016 and discloses based on IFRS from Q1 FY2016.

Amounts less than ¥ 100 million are rounded down.

Overview



Sales revenue	¥ 105.4 billion	+6.9%, year-on-year
Core operating profit	¥ 29.0 billion	+15.1%, year-on-year
Net profit attributable to owners of the Company	¥ 21.9 billion	+18.4%, year-on-year



- Year-on-year increase in sales revenue and profits at all levels
- Sales revenue of priority products: increased by ¥7.0b, y-o-y
- Royalty income of Gilenya and INVOKANA: increased by ¥3.4b, y-o-y, in despite of strong yen
- MCI-186 for ALS: NDA filed in the US in June
- Remicade: approved for increased dose in psoriasis in May
- Canagliflozin: received "Minister of Economy, Trade and Industry Award" at the FY2016 National Commendation for Invention

Q1 FY2016 Financial Results





Mitsubishi Tanabe Pharma

	FY2016	FY2015	Increase/decrease		1H forecasts*	Achieved
	Billion yen	Billion yen	Billion yen	%	Billion yen	%
Sales revenue	105.4	98.6	+ 6.8	+ 6.9	193.0	54.7
(Overseas sales revenue)	25.0	22.2	+2.8	+12.8	48.1	52.1
Overseas sales ratio	23.8%	22.5%			24.9%	
Cost of sales	40.0	35.4	+4.5	+12.8	72.5	55.2
Sales cost ratio	38.0%	36.0%			37.6%	
Gross profit	65.4	63.1	+ 2.2	+ 3.6	120.5	54.3
Core operating profit	29.0	25.2	+ 3.8	+ 15.1	38.0	76.4
Net profit attributable to owners of the Company	21.9	18.4	+ 3.4	+ 18.4	28.5	76.9

<averag< th=""><th colspan="9"><average exchange="" rate=""></average></th></averag<>	<average exchange="" rate=""></average>								
	FY2016	FY2015	FY2016, planned						
US \$	¥107.87	¥121.73	¥110						

*: Announced on May 11,2016 in the financial results of FY2015


Q1 FY2016 Business Results

Open Up the **Future**



Mitsubishi Tanabe Pharma

Sales Revenues Trends



Q1 FY2016 Business Results

Royalty income, etc.

Open Up the **Future**



Mitsubishi Tanabe Pharma

19.8 JPY b 16.3 0.9 20.0 4.9 0.6 4.5 15.0 10.0 13.8 11.2 5.0 0.0 Q1 FY2015 Q1 FY2016 Gilenya INVOKANA/INVOKAMET Others <Average exchange rate> FY2015 FY2016 US\$ ¥121.73 ¥107.87

Q1 FY2016 Business Results

Open Up the **Future**

Cost of Sales, SG&A Expense, Core Operating Profit *Mitsubishi Tanabe Pharma*

	FY2016	FY2015	Increase/c	decrease	Forecasts*	Achieved
	Billion yen	Billion yen	Billion yen	%	Billion yen	
Sales revenue	105.4	98.6	+ 6.8	+ 6.9	193.0	54.7
Cost of Sales	40.0	35.4	+ 4.5	+ 12.8	72.5	55.2
Sales cost ratio	38.0%	36.0%			37.6%	
Gross profit	65.4	63.1	+ 2.2	+ 3.6	120.5	54.3
SG&A expense	21.5	21.7	-0.1	-0.6	48.0	45.0
R&D expense	14.5	15.6	-1.1	-7.3	33.5	43.3
Other income and expense ^{*2}	- 0.3	- 0.5	+ 0.2	-	- 1.0	-
Core operating profit	29.0	25.2	+ 3.8	+ 15.1	38.0	76.4
Total labor costs	17.1	19.5	-2.4	-12.3	37.5	45.8

*1: Announced on May 11, 2016 in the financial results of FY2015

*2: Negative signs indicate expense and loss.

Non-recurring items, Net Profit





Mitsubishi Tanabe Pharma

	FY2016	FY2015	Increase/decrease		Forecasts*1	Achieved
	Billion yen	Billion yen	Billion yen	%	Billion yen	%
Core operating profit	29.0	25.2	+ 3.8	+ 15.1	38.0	76.4
Non-recurring items*2	0.1	-	+ 0.1	-	-	-
Operating profit	29.2	25.2	+ 3.9	+ 15.9	38.0	76.9
Financial income	1.2	1.1	+ 0.1	+ 9.4	0.6	214.7
Financial expense	0.2	0.9	- 0.7	-78.1	0.1	201.0
Net profit attributable to owners of the Company	21.9	18.4	+ 3.4	+ 18.4	28.5	76.9

*1: Announced on May 11, 2016 in the financial results of FY2015

*2: Negative signs indicate expense and loss.

Open Up the Future

Development Pipeline

8

Development Pipeline Progress of Development Pipeline

Open Up the Future



Mitsubishi Tanabe Pharma

	Product name/ development code	MOA (indications)	Area	P1	P2	Р3	Filed	Appro ved
	Remicade	Anti-human TNFα monoclonal antibody (Psoriasis: increased dose)	Japan					
In-house	MCI-186	Free radical scavenger (ALS)	US					
	MT-7117	Dermatologicals, etc. (Inflammatory diseases, autoimmune diseases, etc.)	Europe					





Mitsubishi Tanabe Pharma

Open Up the Future

Becoming a company that works with a sense of speed and is the first to deliver differentiated value



Open Up the Future



Appendix

Breakdown of Sales Revenue





Mitsubishi Tanabe Pharma

	FY2016	FY2015	Increase/decrease		1H forecasts*	Achieved
	Billion yen	Billion yen	Billion yen	%	Billion yen	%
Sales revenue	105.4	98.6	+ 6.8	+ 6.9	193.0	54.7
(Overseas)	25.0	22.2	+ 2.8	+ 12.8	48.1	52.1
Domestic ethical drugs	78.4	74.2	+ 4.1	+ 5.6	141.1	55.5
Overseas ethical drugs	5.5	6.1	- 0.6	- 9.8	10.2	54.5
Royalty income, etc.	19.8	16.3	+ 3.4	+ 20.8	38.2	51.7
OTC products	1.0	1.1	- 0.1	- 13.0	2.2	45.0
Others	0.6	0.6	0.0	+ 2.4	1.0	65.8

*: Announced on May 11, 2016 in the financial results of FY2015.

Appendix

Sales Revenue of Domestic Ethical Drugs





Mitsubishi Tanabe Pharma

	FY2016	FY2015	Increase/decrease		1H forecasts*	Achieved
	Billion yen	Billion yen	Billion yen	%	Billion yen	%
Remicade	17.3	16.8	+ 0.5	+ 3.0	31.6	54.8
Simponi	6.3	3.0	+ 3.2	+ 108.9	11.2	56.0
Talion	4.1	3.5	+ 0.5	+ 15.6	6.6	61.6
Tenelia	3.8	2.9	+ 0.8	+ 30.1	8.3	46.6
Lexapro	2.8	2.1	+ 0.7	+ 34.0	5.6	50.7
Imusera	1.3	0.9	+ 0.3	+ 34.1	2.2	59.0
Canaglu	0.7	0.0	+ 0.7	-	1.6	42.7
Total of priority products	36.5	29.5	+ 7.0	+ 23.7	67.4	54.2
Tetrabik	2.7	1.9	+ 0.8	+ 42.7	3.9	69.0
Mearubik	1.7	1.4	+ 0.2	+ 18.9	2.3	74.7
Varicella vaccine	1.4	1.7	- 0.3	- 19.2	2.9	49.5
JEBIK V	1.2	0.9	+ 0.3	+ 35.6	2.1	61.1
Influenza vaccine	-0.1	-0.0	-0.0	-	2.0	-
Total of vaccines	7.3	6.2	+ 1.0	+ 16.6	13.7	53.3
Total of priority products and vaccines	43.8	35.8	+ 8.0	+ 22.5	81.2	54.0

*: Announced on May 11, 2016 in the financial results of FY2015

Appendix


Gilenya





Mitsubishi Tanabe Pharma

- Novartis worldwide sales in April to June, 2016: \$811m (\$700m, the same period of the last year)
- MTPC royalty income in Q1 FY2016: ¥13.8b



Appendix **INVOKANA/INVOKAMET**


Open Up the **Future**



Mitsubishi Tanabe Pharma

Johnson & Johnson sales in April to June, 2016: \$383m (the same period the last year: \$318m) INVOKANA/INVOKAMET TRx share 6.3% in defined U.S. T2D market

MTPC royalty income in Q1 FY2016: ¥4.9b



Cautionary Statement

The statements contained in this presentation is based on a number of assumptions and belief in light of the information currently available to management of the company and is subject to significant risks and uncertainties.